Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Generic Claims:
advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes…
Red Flags:
FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified…
Semantic Drift Patterns:
homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations:
specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations…
Genentech (Rozlytrek)
(https://rozlytrek.com) 📸 Data Snapshot: June 19, 2026Analyze the raw signals below. How would a machine score this business’s credibility?
Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.
🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE Genentech: Rozlytrek® (entrectinib) – Information for Patients (https://rozlytrek.com)
Title
Genentech: Rozlytrek® (entrectinib) – Information for Patients
Meta
Find important safety information and patient resources for all of our currently marketed medicines.
H1 Rozlytrek®
entrectinib
H2 Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.
H2 Support & Resources
H2 Indications & Important Safety Information
H4 SUPPORT
H4 SUPPORT
H4 What is ROZLYTREK® (entrectinib)?
H4 Important Safety Information
H4 Before taking ROZLYTREK, tell your healthcare provider about all your medical conditions, including if you:
H4 What should I avoid while taking ROZLYTREK?
H4 What are some possible side effects of ROZLYTREK?
H4 The most common side effects of ROZLYTREK include:
NAV_HEADING_REPEATED_BODY_FOOTER Genentech: Rozlytrek® (entrectinib) – Information for Patients (https://rozlytrek.com/patients/medicine-information-support/)
Title
Genentech: Rozlytrek® (entrectinib) – Information for Patients
Meta
Find important safety information and patient resources for all of our currently marketed medicines.
H1 Rozlytrek®
entrectinib
H2 Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.
H2 Support & Resources
H2 Indications & Important Safety Information
H4 SUPPORT
H4 SUPPORT
H4 What is ROZLYTREK® (entrectinib)?
H4 Important Safety Information
H4 Before taking ROZLYTREK, tell your healthcare provider about all your medical conditions, including if you:
H4 What should I avoid while taking ROZLYTREK?
H4 What are some possible side effects of ROZLYTREK?
H4 The most common side effects of ROZLYTREK include:
NAV_HEADING_REPEATED_BODY_FOOTER Genentech: Rozlytrek® (entrectinib) – Information for Patients (https://rozlytrek.com/patients/)
Title
Genentech: Rozlytrek® (entrectinib) – Information for Patients
Meta
Find important safety information and patient resources for all of our currently marketed medicines.
H1 Rozlytrek®
entrectinib
H2 Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.
H2 Support & Resources
H2 Indications & Important Safety Information
H4 SUPPORT
H4 SUPPORT
H4 What is ROZLYTREK® (entrectinib)?
H4 Important Safety Information
H4 Before taking ROZLYTREK, tell your healthcare provider about all your medical conditions, including if you:
H4 What should I avoid while taking ROZLYTREK?
H4 What are some possible side effects of ROZLYTREK?
H4 The most common side effects of ROZLYTREK include:
NAV_HEADING_REPEATED_BODY_FOOTER Genentech: Rozlytrek® (entrectinib) – Information for Patients (https://rozlytrek.com/patients/medicines/)
Title
Genentech: Rozlytrek® (entrectinib) – Information for Patients
Meta
Find important safety information and patient resources for all of our currently marketed medicines.
H1 Rozlytrek®
entrectinib
H2 Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.
H2 Support & Resources
H2 Indications & Important Safety Information
H4 SUPPORT
H4 SUPPORT
H4 What is ROZLYTREK® (entrectinib)?
H4 Important Safety Information
H4 Before taking ROZLYTREK, tell your healthcare provider about all your medical conditions, including if you:
H4 What should I avoid while taking ROZLYTREK?
H4 What are some possible side effects of ROZLYTREK?
H4 The most common side effects of ROZLYTREK include:
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://rozlytrek.com) Genentech: Rozlytrek® (entrectinib) – Information for Patients
Patient Medical Professional Patients / Our Medicines [H1] Rozlytrek® entrectinib Full Prescribing Information Patient Information Instructions for Use | Capsules For Oral Use Instructions for Use | Oral Pellets [H2] Support & Resources Report side effects for your Rozlytrek prescription Report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects or harmful experiences to Genentech at (888) 835-2555 or here. Get help paying for your Rozlytrek prescription [H4] SUPPORT Genentech Patient Resource CenterOur center dedicated to getting patients and caregivers to the right resources. Call us at (877) 436-3683 or (877) GENENTECH, Monday-Friday, 6am-5pm PT. Genentech Access Solutions This service offers coverage support, patient assistance, and other useful information. Genentech Patient Foundation Provides free medicine to patients without insurance coverage or who can't pay for their Genentech medicine. Get answers to your questions about your Rozlytrek prescription [H4] SUPPORT Medicine Information SupportAsk about possible side effects and any other medical questions related to your prescribed Genentech medicine. Call a nurse at (800) 821-8590, Monday-Friday, 5am-5pm PT. Chat with a nurse using our live chat feature, Monday-Friday, 5am-5pm PT.Email a nurse by filling out this form. [H2] Indications & Important Safety Information [H4] What is ROZLYTREK® (entrectinib)? ROZLYTREK is a prescription medicine used to treat: Adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by an abnormal ROS1 gene. Adults and children 1 month of age and older with solid tumors (cancer) that: are caused by certain abnormal NTRK genes, and have spread or if surgery to remove their cancer is likely to cause severe complications, and there is no satisfactory alternative treatment option or the cancer grew or spread on other treatment. It is not known if ROZLYTREK is safe and effective in children with ROS1 NSCLC or in children under 1 month of age with NTRK solid tumors. The approval of ROZLYTREK was based on a study that measured response to treatment and duration of response. Continued approval for this use may depend on the results of an ongoing study to confirm the benefit of ROZLYTREK for this use. [H4] Important Safety Information What is the most important information I should know about ROZLYTREK? ROZLYTREK may cause serious side effects, including: Congestive heart failure. ROZLYTREK may cause congestive heart failure or make the congestive heart failure that you already have worse. Your healthcare provider will do tests before your treatment and may do tests during your treatment with ROZLYTREK to check your heart function. Tell your healthcare provider right away if you have any of the following signs and symptoms of congestive heart failure: persistent coughing or wheezing trouble breathing when lying down sudden weight gain increasing shortness of breath tiredness, weakness, or fatigue swelling in ankles, feet, or legs Central nervous system (CNS) effects. ROZLYTREK may cause dizziness, changes in your mood, or may affect how you think and cause confusion, hallucinations, and problems with concentration, attention, memory, speaking, understanding what you hear or read, and sleep. Tell your healthcare provider right away if you develop any of these symptoms. Bone fractures. ROZLYTREK may increase your risk for bone fractures. Bone fractures may happen with or without a fall or other injury. Tell your healthcare provider if you develop pain, changes in movement, or bone abnormalities. Liver problems (hepatotoxicity). Your healthcare provider will do blood tests to check your liver function during treatment with ROZLYTREK. Tell your healthcare provider right away if you develop any of the following sympptoms of liver problems: loss of appetite nausea or vomiting pain in the upper right stomach area yellowing of your skin or the white part of your eyes dark urine Increased uric acid level in your blood (hyperuricemia). ROZLYTREK may cause too much of uric acid in your blood. Your healthcare provider will do tests before and during your treatment with ROZLYTREK to check the uric acid level in your blood. Your healthcare provider may prescribe medications if you have high blood uric acid levels. Tell your healthcare provider if you develop any of the following symptoms of hyperuricemia: red, hot, tender, or swollen joints, especially in your big toe pain in your stomach-area or sides nausea or vomiting pink or brown urine Changes in the electrical activity of your heart called QT prolongation. QT prolongation can cause irregular heartbeats that can be life-threatening. Your healthcare provider will do tests before and during your treatment with ROZLYTREK to check the electrical activity of your heart and your body salts (electrolytes). Tell your healthcare provider right away if you feel faint, lightheaded, dizzy, or feel your heart beating irregularly or fast during your treatment with ROZLYTREK. These may be symptoms related to QT prolongation. Vision problems. ROZLYTREK may cause vision problems. Your healthcare provider may stop ROZLYTREK and refer you to an eye specialist if you develop severe vision problems during treatment with ROZLYTREK. Tell your healthcare provider right away if you develop any loss of vision or any change in vision, including: double vision blurry vision new or increased floaters seeing flashes of light light hurting your eyes Your healthcare provider may temporarily stop treatment, decrease your dose, or permanently stop ROZLYTREK if you develop certain side effects during treatment with ROZLYTREK. [H4] Before taking ROZLYTREK, tell your healthcare provider about all your medical conditions, including if you: have liver or kidney problems have any heart problems, including a condition called long QT syndrome have nervous system (neurological) problems have or have had eye or vision problems are pregnant or plan to become pregnant. ROZLYTREK can cause harm to your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with ROZLYTREK. Females who can become pregnant: Your healthcare provider will do a pregnancy test before you start treatment with ROZLYTREK. Use effective birth control (contraception) during treatment with ROZLYTREK and for at least 5 weeks after the last dose. Males with female partners that can become pregnant: Use effective birth control (contraception) during treatment with ROZLYTREK and for 3 months after the last dose. are breastfeeding or plan to breastfeed. It is not known if ROZLYTREK passes into your breast milk. Do not breastfeed during treatment with ROZLYTREK and for 7 days (1 week) after the last dose of ROZLYTREK. Talk to your healthcare provider about the best way to feed your baby during this time. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. Taking ROZLYTREK with certain other medicines may affect the amount of ROZLYTREK or other medicine in your blood and may cause side effects or affect the way that ROZLYTREK or the other medicine work. Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine. [H4] What should I avoid while taking ROZLYTREK? You should not drink grapefruit juice or eat grapefruit during your treatment with ROZLYTREK. It may increase the amount of entrectinib in your blood to a harmful level and increase your chance of getting side effects. Do not drive or operate heavy machinery until you know how ROZLYTREK affects you. If you experience dizziness, fainting, tiredness, blurred vision, memory loss, changes in mental status, confusion, or hallucinations, do not drive or operate heavy machines until your symptoms resolve. [H4] What are some possible side effects of ROZLYTREK? [H4] The most common side effects of ROZLYTREK include: tiredness constipation change in taste swelling dizziness diarrhea nausea abnormal touch sensation shortness of breath muscle pain confusion, mental status changes, memory problems, and hallucinations weight gain cough vomiting fever joint pain vision changes These are not all the possible side effects of ROZLYTREK. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555. Please see the ROZLYTREK full Prescribing Information for additional Important Safety Information.
8974 chars
SUB-PAGE (https://rozlytrek.com/patients/medicine-information-support/) Genentech: Rozlytrek® (entrectinib) – Information for Patients
Patient Medical Professional Patients / Our Medicines [H1] Rozlytrek® entrectinib Full Prescribing Information Patient Information Instructions for Use | Capsules For Oral Use Instructions for Use | Oral Pellets [H2] Support & Resources Report side effects for your Rozlytrek prescription Report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects or harmful experiences to Genentech at (888) 835-2555 or here. Get help paying for your Rozlytrek prescription [H4] SUPPORT Genentech Patient Resource CenterOur center dedicated to getting patients and caregivers to the right resources. Call us at (877) 436-3683 or (877) GENENTECH, Monday-Friday, 6am-5pm PT. Genentech Access Solutions This service offers coverage support, patient assistance, and other useful information. Genentech Patient Foundation Provides free medicine to patients without insurance coverage or who can't pay for their Genentech medicine. Get answers to your questions about your Rozlytrek prescription [H4] SUPPORT Medicine Information SupportAsk about possible side effects and any other medical questions related to your prescribed Genentech medicine. Call a nurse at (800) 821-8590, Monday-Friday, 5am-5pm PT. Chat with a nurse using our live chat feature, Monday-Friday, 5am-5pm PT.Email a nurse by filling out this form. [H2] Indications & Important Safety Information [H4] What is ROZLYTREK® (entrectinib)? ROZLYTREK is a prescription medicine used to treat: Adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by an abnormal ROS1 gene. Adults and children 1 month of age and older with solid tumors (cancer) that: are caused by certain abnormal NTRK genes, and have spread or if surgery to remove their cancer is likely to cause severe complications, and there is no satisfactory alternative treatment option or the cancer grew or spread on other treatment. It is not known if ROZLYTREK is safe and effective in children with ROS1 NSCLC or in children under 1 month of age with NTRK solid tumors. The approval of ROZLYTREK was based on a study that measured response to treatment and duration of response. Continued approval for this use may depend on the results of an ongoing study to confirm the benefit of ROZLYTREK for this use. [H4] Important Safety Information What is the most important information I should know about ROZLYTREK? ROZLYTREK may cause serious side effects, including: Congestive heart failure. ROZLYTREK may cause congestive heart failure or make the congestive heart failure that you already have worse. Your healthcare provider will do tests before your treatment and may do tests during your treatment with ROZLYTREK to check your heart function. Tell your healthcare provider right away if you have any of the following signs and symptoms of congestive heart failure: persistent coughing or wheezing trouble breathing when lying down sudden weight gain increasing shortness of breath tiredness, weakness, or fatigue swelling in ankles, feet, or legs Central nervous system (CNS) effects. ROZLYTREK may cause dizziness, changes in your mood, or may affect how you think and cause confusion, hallucinations, and problems with concentration, attention, memory, speaking, understanding what you hear or read, and sleep. Tell your healthcare provider right away if you develop any of these symptoms. Bone fractures. ROZLYTREK may increase your risk for bone fractures. Bone fractures may happen with or without a fall or other injury. Tell your healthcare provider if you develop pain, changes in movement, or bone abnormalities. Liver problems (hepatotoxicity). Your healthcare provider will do blood tests to check your liver function during treatment with ROZLYTREK. Tell your healthcare provider right away if you develop any of the following sympptoms of liver problems: loss of appetite nausea or vomiting pain in the upper right stomach area yellowing of your skin or the white part of your eyes dark urine Increased uric acid level in your blood (hyperuricemia). ROZLYTREK may cause too much of uric acid in your blood. Your healthcare provider will do tests before and during your treatment with ROZLYTREK to check the uric acid level in your blood. Your healthcare provider may prescribe medications if you have high blood uric acid levels. Tell your healthcare provider if you develop any of the following symptoms of hyperuricemia: red, hot, tender, or swollen joints, especially in your big toe pain in your stomach-area or sides nausea or vomiting pink or brown urine Changes in the electrical activity of your heart called QT prolongation. QT prolongation can cause irregular heartbeats that can be life-threatening. Your healthcare provider will do tests before and during your treatment with ROZLYTREK to check the electrical activity of your heart and your body salts (electrolytes). Tell your healthcare provider right away if you feel faint, lightheaded, dizzy, or feel your heart beating irregularly or fast during your treatment with ROZLYTREK. These may be symptoms related to QT prolongation. Vision problems. ROZLYTREK may cause vision problems. Your healthcare provider may stop ROZLYTREK and refer you to an eye specialist if you develop severe vision problems during treatment with ROZLYTREK. Tell your healthcare provider right away if you develop any loss of vision or any change in vision, including: double vision blurry vision new or increased floaters seeing flashes of light light hurting your eyes Your healthcare provider may temporarily stop treatment, decrease your dose, or permanently stop ROZLYTREK if you develop certain side effects during treatment with ROZLYTREK. [H4] Before taking ROZLYTREK, tell your healthcare provider about all your medical conditions, including if you: have liver or kidney problems have any heart problems, including a condition called long QT syndrome have nervous system (neurological) problems have or have had eye or vision problems are pregnant or plan to become pregnant. ROZLYTREK can cause harm to your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with ROZLYTREK. Females who can become pregnant: Your healthcare provider will do a pregnancy test before you start treatment with ROZLYTREK. Use effective birth control (contraception) during treatment with ROZLYTREK and for at least 5 weeks after the last dose. Males with female partners that can become pregnant: Use effective birth control (contraception) during treatment with ROZLYTREK and for 3 months after the last dose. are breastfeeding or plan to breastfeed. It is not known if ROZLYTREK passes into your breast milk. Do not breastfeed during treatment with ROZLYTREK and for 7 days (1 week) after the last dose of ROZLYTREK. Talk to your healthcare provider about the best way to feed your baby during this time. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. Taking ROZLYTREK with certain other medicines may affect the amount of ROZLYTREK or other medicine in your blood and may cause side effects or affect the way that ROZLYTREK or the other medicine work. Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine. [H4] What should I avoid while taking ROZLYTREK? You should not drink grapefruit juice or eat grapefruit during your treatment with ROZLYTREK. It may increase the amount of entrectinib in your blood to a harmful level and increase your chance of getting side effects. Do not drive or operate heavy machinery until you know how ROZLYTREK affects you. If you experience dizziness, fainting, tiredness, blurred vision, memory loss, changes in mental status, confusion, or hallucinations, do not drive or operate heavy machines until your symptoms resolve. [H4] What are some possible side effects of ROZLYTREK? [H4] The most common side effects of ROZLYTREK include: tiredness constipation change in taste swelling dizziness diarrhea nausea abnormal touch sensation shortness of breath muscle pain confusion, mental status changes, memory problems, and hallucinations weight gain cough vomiting fever joint pain vision changes These are not all the possible side effects of ROZLYTREK. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555. Please see the ROZLYTREK full Prescribing Information for additional Important Safety Information.
8974 chars
SUB-PAGE (https://rozlytrek.com/patients/) Genentech: Rozlytrek® (entrectinib) – Information for Patients
Patient Medical Professional Patients / Our Medicines [H1] Rozlytrek® entrectinib Full Prescribing Information Patient Information Instructions for Use | Capsules For Oral Use Instructions for Use | Oral Pellets [H2] Support & Resources Report side effects for your Rozlytrek prescription Report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects or harmful experiences to Genentech at (888) 835-2555 or here. Get help paying for your Rozlytrek prescription [H4] SUPPORT Genentech Patient Resource CenterOur center dedicated to getting patients and caregivers to the right resources. Call us at (877) 436-3683 or (877) GENENTECH, Monday-Friday, 6am-5pm PT. Genentech Access Solutions This service offers coverage support, patient assistance, and other useful information. Genentech Patient Foundation Provides free medicine to patients without insurance coverage or who can't pay for their Genentech medicine. Get answers to your questions about your Rozlytrek prescription [H4] SUPPORT Medicine Information SupportAsk about possible side effects and any other medical questions related to your prescribed Genentech medicine. Call a nurse at (800) 821-8590, Monday-Friday, 5am-5pm PT. Chat with a nurse using our live chat feature, Monday-Friday, 5am-5pm PT.Email a nurse by filling out this form. [H2] Indications & Important Safety Information [H4] What is ROZLYTREK® (entrectinib)? ROZLYTREK is a prescription medicine used to treat: Adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by an abnormal ROS1 gene. Adults and children 1 month of age and older with solid tumors (cancer) that: are caused by certain abnormal NTRK genes, and have spread or if surgery to remove their cancer is likely to cause severe complications, and there is no satisfactory alternative treatment option or the cancer grew or spread on other treatment. It is not known if ROZLYTREK is safe and effective in children with ROS1 NSCLC or in children under 1 month of age with NTRK solid tumors. The approval of ROZLYTREK was based on a study that measured response to treatment and duration of response. Continued approval for this use may depend on the results of an ongoing study to confirm the benefit of ROZLYTREK for this use. [H4] Important Safety Information What is the most important information I should know about ROZLYTREK? ROZLYTREK may cause serious side effects, including: Congestive heart failure. ROZLYTREK may cause congestive heart failure or make the congestive heart failure that you already have worse. Your healthcare provider will do tests before your treatment and may do tests during your treatment with ROZLYTREK to check your heart function. Tell your healthcare provider right away if you have any of the following signs and symptoms of congestive heart failure: persistent coughing or wheezing trouble breathing when lying down sudden weight gain increasing shortness of breath tiredness, weakness, or fatigue swelling in ankles, feet, or legs Central nervous system (CNS) effects. ROZLYTREK may cause dizziness, changes in your mood, or may affect how you think and cause confusion, hallucinations, and problems with concentration, attention, memory, speaking, understanding what you hear or read, and sleep. Tell your healthcare provider right away if you develop any of these symptoms. Bone fractures. ROZLYTREK may increase your risk for bone fractures. Bone fractures may happen with or without a fall or other injury. Tell your healthcare provider if you develop pain, changes in movement, or bone abnormalities. Liver problems (hepatotoxicity). Your healthcare provider will do blood tests to check your liver function during treatment with ROZLYTREK. Tell your healthcare provider right away if you develop any of the following sympptoms of liver problems: loss of appetite nausea or vomiting pain in the upper right stomach area yellowing of your skin or the white part of your eyes dark urine Increased uric acid level in your blood (hyperuricemia). ROZLYTREK may cause too much of uric acid in your blood. Your healthcare provider will do tests before and during your treatment with ROZLYTREK to check the uric acid level in your blood. Your healthcare provider may prescribe medications if you have high blood uric acid levels. Tell your healthcare provider if you develop any of the following symptoms of hyperuricemia: red, hot, tender, or swollen joints, especially in your big toe pain in your stomach-area or sides nausea or vomiting pink or brown urine Changes in the electrical activity of your heart called QT prolongation. QT prolongation can cause irregular heartbeats that can be life-threatening. Your healthcare provider will do tests before and during your treatment with ROZLYTREK to check the electrical activity of your heart and your body salts (electrolytes). Tell your healthcare provider right away if you feel faint, lightheaded, dizzy, or feel your heart beating irregularly or fast during your treatment with ROZLYTREK. These may be symptoms related to QT prolongation. Vision problems. ROZLYTREK may cause vision problems. Your healthcare provider may stop ROZLYTREK and refer you to an eye specialist if you develop severe vision problems during treatment with ROZLYTREK. Tell your healthcare provider right away if you develop any loss of vision or any change in vision, including: double vision blurry vision new or increased floaters seeing flashes of light light hurting your eyes Your healthcare provider may temporarily stop treatment, decrease your dose, or permanently stop ROZLYTREK if you develop certain side effects during treatment with ROZLYTREK. [H4] Before taking ROZLYTREK, tell your healthcare provider about all your medical conditions, including if you: have liver or kidney problems have any heart problems, including a condition called long QT syndrome have nervous system (neurological) problems have or have had eye or vision problems are pregnant or plan to become pregnant. ROZLYTREK can cause harm to your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with ROZLYTREK. Females who can become pregnant: Your healthcare provider will do a pregnancy test before you start treatment with ROZLYTREK. Use effective birth control (contraception) during treatment with ROZLYTREK and for at least 5 weeks after the last dose. Males with female partners that can become pregnant: Use effective birth control (contraception) during treatment with ROZLYTREK and for 3 months after the last dose. are breastfeeding or plan to breastfeed. It is not known if ROZLYTREK passes into your breast milk. Do not breastfeed during treatment with ROZLYTREK and for 7 days (1 week) after the last dose of ROZLYTREK. Talk to your healthcare provider about the best way to feed your baby during this time. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. Taking ROZLYTREK with certain other medicines may affect the amount of ROZLYTREK or other medicine in your blood and may cause side effects or affect the way that ROZLYTREK or the other medicine work. Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine. [H4] What should I avoid while taking ROZLYTREK? You should not drink grapefruit juice or eat grapefruit during your treatment with ROZLYTREK. It may increase the amount of entrectinib in your blood to a harmful level and increase your chance of getting side effects. Do not drive or operate heavy machinery until you know how ROZLYTREK affects you. If you experience dizziness, fainting, tiredness, blurred vision, memory loss, changes in mental status, confusion, or hallucinations, do not drive or operate heavy machines until your symptoms resolve. [H4] What are some possible side effects of ROZLYTREK? [H4] The most common side effects of ROZLYTREK include: tiredness constipation change in taste swelling dizziness diarrhea nausea abnormal touch sensation shortness of breath muscle pain confusion, mental status changes, memory problems, and hallucinations weight gain cough vomiting fever joint pain vision changes These are not all the possible side effects of ROZLYTREK. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555. Please see the ROZLYTREK full Prescribing Information for additional Important Safety Information.
8974 chars
SUB-PAGE (https://rozlytrek.com/patients/medicines/) Genentech: Rozlytrek® (entrectinib) – Information for Patients
Patient Medical Professional Patients / Our Medicines [H1] Rozlytrek® entrectinib Full Prescribing Information Patient Information Instructions for Use | Capsules For Oral Use Instructions for Use | Oral Pellets [H2] Support & Resources Report side effects for your Rozlytrek prescription Report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects or harmful experiences to Genentech at (888) 835-2555 or here. Get help paying for your Rozlytrek prescription [H4] SUPPORT Genentech Patient Resource CenterOur center dedicated to getting patients and caregivers to the right resources. Call us at (877) 436-3683 or (877) GENENTECH, Monday-Friday, 6am-5pm PT. Genentech Access Solutions This service offers coverage support, patient assistance, and other useful information. Genentech Patient Foundation Provides free medicine to patients without insurance coverage or who can't pay for their Genentech medicine. Get answers to your questions about your Rozlytrek prescription [H4] SUPPORT Medicine Information SupportAsk about possible side effects and any other medical questions related to your prescribed Genentech medicine. Call a nurse at (800) 821-8590, Monday-Friday, 5am-5pm PT. Chat with a nurse using our live chat feature, Monday-Friday, 5am-5pm PT.Email a nurse by filling out this form. [H2] Indications & Important Safety Information [H4] What is ROZLYTREK® (entrectinib)? ROZLYTREK is a prescription medicine used to treat: Adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by an abnormal ROS1 gene. Adults and children 1 month of age and older with solid tumors (cancer) that: are caused by certain abnormal NTRK genes, and have spread or if surgery to remove their cancer is likely to cause severe complications, and there is no satisfactory alternative treatment option or the cancer grew or spread on other treatment. It is not known if ROZLYTREK is safe and effective in children with ROS1 NSCLC or in children under 1 month of age with NTRK solid tumors. The approval of ROZLYTREK was based on a study that measured response to treatment and duration of response. Continued approval for this use may depend on the results of an ongoing study to confirm the benefit of ROZLYTREK for this use. [H4] Important Safety Information What is the most important information I should know about ROZLYTREK? ROZLYTREK may cause serious side effects, including: Congestive heart failure. ROZLYTREK may cause congestive heart failure or make the congestive heart failure that you already have worse. Your healthcare provider will do tests before your treatment and may do tests during your treatment with ROZLYTREK to check your heart function. Tell your healthcare provider right away if you have any of the following signs and symptoms of congestive heart failure: persistent coughing or wheezing trouble breathing when lying down sudden weight gain increasing shortness of breath tiredness, weakness, or fatigue swelling in ankles, feet, or legs Central nervous system (CNS) effects. ROZLYTREK may cause dizziness, changes in your mood, or may affect how you think and cause confusion, hallucinations, and problems with concentration, attention, memory, speaking, understanding what you hear or read, and sleep. Tell your healthcare provider right away if you develop any of these symptoms. Bone fractures. ROZLYTREK may increase your risk for bone fractures. Bone fractures may happen with or without a fall or other injury. Tell your healthcare provider if you develop pain, changes in movement, or bone abnormalities. Liver problems (hepatotoxicity). Your healthcare provider will do blood tests to check your liver function during treatment with ROZLYTREK. Tell your healthcare provider right away if you develop any of the following sympptoms of liver problems: loss of appetite nausea or vomiting pain in the upper right stomach area yellowing of your skin or the white part of your eyes dark urine Increased uric acid level in your blood (hyperuricemia). ROZLYTREK may cause too much of uric acid in your blood. Your healthcare provider will do tests before and during your treatment with ROZLYTREK to check the uric acid level in your blood. Your healthcare provider may prescribe medications if you have high blood uric acid levels. Tell your healthcare provider if you develop any of the following symptoms of hyperuricemia: red, hot, tender, or swollen joints, especially in your big toe pain in your stomach-area or sides nausea or vomiting pink or brown urine Changes in the electrical activity of your heart called QT prolongation. QT prolongation can cause irregular heartbeats that can be life-threatening. Your healthcare provider will do tests before and during your treatment with ROZLYTREK to check the electrical activity of your heart and your body salts (electrolytes). Tell your healthcare provider right away if you feel faint, lightheaded, dizzy, or feel your heart beating irregularly or fast during your treatment with ROZLYTREK. These may be symptoms related to QT prolongation. Vision problems. ROZLYTREK may cause vision problems. Your healthcare provider may stop ROZLYTREK and refer you to an eye specialist if you develop severe vision problems during treatment with ROZLYTREK. Tell your healthcare provider right away if you develop any loss of vision or any change in vision, including: double vision blurry vision new or increased floaters seeing flashes of light light hurting your eyes Your healthcare provider may temporarily stop treatment, decrease your dose, or permanently stop ROZLYTREK if you develop certain side effects during treatment with ROZLYTREK. [H4] Before taking ROZLYTREK, tell your healthcare provider about all your medical conditions, including if you: have liver or kidney problems have any heart problems, including a condition called long QT syndrome have nervous system (neurological) problems have or have had eye or vision problems are pregnant or plan to become pregnant. ROZLYTREK can cause harm to your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with ROZLYTREK. Females who can become pregnant: Your healthcare provider will do a pregnancy test before you start treatment with ROZLYTREK. Use effective birth control (contraception) during treatment with ROZLYTREK and for at least 5 weeks after the last dose. Males with female partners that can become pregnant: Use effective birth control (contraception) during treatment with ROZLYTREK and for 3 months after the last dose. are breastfeeding or plan to breastfeed. It is not known if ROZLYTREK passes into your breast milk. Do not breastfeed during treatment with ROZLYTREK and for 7 days (1 week) after the last dose of ROZLYTREK. Talk to your healthcare provider about the best way to feed your baby during this time. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. Taking ROZLYTREK with certain other medicines may affect the amount of ROZLYTREK or other medicine in your blood and may cause side effects or affect the way that ROZLYTREK or the other medicine work. Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine. [H4] What should I avoid while taking ROZLYTREK? You should not drink grapefruit juice or eat grapefruit during your treatment with ROZLYTREK. It may increase the amount of entrectinib in your blood to a harmful level and increase your chance of getting side effects. Do not drive or operate heavy machinery until you know how ROZLYTREK affects you. If you experience dizziness, fainting, tiredness, blurred vision, memory loss, changes in mental status, confusion, or hallucinations, do not drive or operate heavy machines until your symptoms resolve. [H4] What are some possible side effects of ROZLYTREK? [H4] The most common side effects of ROZLYTREK include: tiredness constipation change in taste swelling dizziness diarrhea nausea abnormal touch sensation shortness of breath muscle pain confusion, mental status changes, memory problems, and hallucinations weight gain cough vomiting fever joint pain vision changes These are not all the possible side effects of ROZLYTREK. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555. Please see the ROZLYTREK full Prescribing Information for additional Important Safety Information.
8974 chars
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
12Review mentions (all pages)
4External proof links (all pages)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 3 | 1 |
| /patients/medicine-information-support/ | 3 | 1 |
| /patients/ | 3 | 1 |
| /patients/medicines/ | 3 | 1 |
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage — no schema detected (entity gap)
/patients/medicine-information-support/ — no schema detected (entity gap)
/patients/ — no schema detected (entity gap)
/patients/medicines/ — no schema detected (entity gap)
Your Diagnosis
Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.
Information Density
0 / 30
Read the Narrative & headings: do hard facts (prices, dates, numbers) outweigh fluff power-words?
Semantic Coherence
0 / 20
Compare the homepage promise against the sub-page reality. Do they hold the same line?
Trust & Proof
0 / 20
Weigh review mentions against actual external proof links. Claims without verification = theatre.
Commodity Fingerprint
0 / 15
Check headings & narrative against the industry clichés in the setup above.
Identity & Authority
0 / 15
Inspect the schema: is there real Organization/Person identity with sameAs links, or gaps?
Your predicted BS score
0 / 100
Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)
These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.
Information Density
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Semantic Alignment
Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
Trust & Proof
Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
Commodity Fingerprint
Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.
Identity & Authority
Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.
B
BS Level
Medical Devices, Pharma & Biotech
40.7 Avg BS
Based on 784 businesses audited.
BS Detector
Medical Devices, Pharma & Biotech BS: Genentech (Rozlytrek) (rozlytrek.com)
https://rozlytrek.com
📍 Industry: Medical Devices, Pharma & Biotech
9
BS / 100
This is a non-BS site characterized by extreme regulatory transparency and clinical specificity. It prioritizes safety disclosures and molecular indications over marketing fluff, resulting in one of the lowest BS scores possible. The only detectable weaknesses are technical legacy issues and content duplication across URL paths.
Info Density
Power-words vs. Substance ratio.
3
10% BS
Semantic Coherence
Homepage promise vs. Sub-page reality.
2
10% BS
Trust & Proof
Verifiable evidence vs. Trust Theatre.
0
0% BS
Commodity Fingerprint
Detection of industry clichés/templates.
1
7% BS
Identity & Authority
Expert verifiability & Schema depth.
3
20% BS
Implement Organization and Brand schema to provide structured data for search engines and verify corporate identity. Resolve the redundant content issue by providing page-specific details for /medicine-information-support/ rather than mirroring the homepage. Fix the heading hierarchy to ensure H4 tags are nested correctly under H3 tags for better machine readability. Remove the legacy browser warnings for IE10 to modernize the user experience and technical authority.
The site content perfectly aligns with the Pharmaceutical and Biotech industry classification. It focuses entirely on a specific molecular entity, entrectinib, and adheres to strict FDA-mandated disclosure patterns including Indications and Important Safety Information (ISI).
“The score of 9 is driven primarily by technical and structural factors rather than content bullshit. The 'Identity and Authority' pillar (3 points) and 'Information Density' pillar (3 points) were the main contributors due to missing schema and identical content across multiple sub-pages. The site contains zero 'marketing BS,' which is reflected in the near-zero scores for Trust and Commodity pillars.”
Verified Analysis Date: June 19, 2026
© 1EuroSEO Independent Evaluator — Non-Sponsored Result
Analysis Disclosure & Source Attribution
This training module utilizes a snapshot of public data from Genentech (Rozlytrek), captured on June 19, 2026, to demonstrate how machine logic evaluates different types of business narratives.
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.
Notice to Genentech (Rozlytrek): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.
Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://rozlytrek.com to view the most current version of its content and learn from the source what this company is about and what it offers.